MXPA02010974A - Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas. - Google Patents

Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas.

Info

Publication number
MXPA02010974A
MXPA02010974A MXPA02010974A MXPA02010974A MXPA02010974A MX PA02010974 A MXPA02010974 A MX PA02010974A MX PA02010974 A MXPA02010974 A MX PA02010974A MX PA02010974 A MXPA02010974 A MX PA02010974A MX PA02010974 A MXPA02010974 A MX PA02010974A
Authority
MX
Mexico
Prior art keywords
cancer cells
leukotriene
methods
method includes
adenocarcinoma cancer
Prior art date
Application number
MXPA02010974A
Other languages
English (en)
Spanish (es)
Inventor
Thomas E Adrian
Original Assignee
Univ Creighton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Creighton filed Critical Univ Creighton
Publication of MXPA02010974A publication Critical patent/MXPA02010974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MXPA02010974A 2000-05-09 2001-05-08 Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas. MXPA02010974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21934400P 2000-05-09 2000-05-09
PCT/US2001/040697 WO2001085166A1 (en) 2000-05-09 2001-05-08 Methods for inhibiting proliferation and inducing apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
MXPA02010974A true MXPA02010974A (es) 2004-09-06

Family

ID=22818912

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010974A MXPA02010974A (es) 2000-05-09 2001-05-08 Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas.

Country Status (11)

Country Link
EP (1) EP1326605A4 (ko)
JP (1) JP2003532675A (ko)
KR (1) KR20030019372A (ko)
CN (1) CN1237968C (ko)
AU (1) AU2001261832A1 (ko)
BR (1) BR0110473A (ko)
CA (1) CA2408622A1 (ko)
MX (1) MXPA02010974A (ko)
NO (1) NO20025343L (ko)
NZ (1) NZ522387A (ko)
WO (1) WO2001085166A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
EP2034022A1 (en) * 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EA023067B1 (ru) 2012-01-10 2016-04-29 Эли Лилли Энд Компани Соединение, представляющее собой антагонист лейкотриена b
CN110559441A (zh) 2013-04-22 2019-12-13 株式会社栃木临床病理研究所 抗肿瘤剂
KR102423640B1 (ko) 2013-12-20 2022-07-22 노파르티스 아게 Lta4h 억제제로서의 헤테로아릴 부탄산 유도체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
JPH10505348A (ja) * 1994-08-31 1998-05-26 イーライ・リリー・アンド・カンパニー 耐性腫瘍の同定および治療方法
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2041801A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
BR0015490A (pt) * 1999-11-11 2002-07-09 Lilly Co Eli Combinações oncolìticas para o tratamento de câncer

Also Published As

Publication number Publication date
EP1326605A4 (en) 2004-03-17
CN1429111A (zh) 2003-07-09
WO2001085166A1 (en) 2001-11-15
NZ522387A (en) 2003-09-26
CA2408622A1 (en) 2001-11-15
JP2003532675A (ja) 2003-11-05
CN1237968C (zh) 2006-01-25
EP1326605A1 (en) 2003-07-16
NO20025343L (no) 2003-01-09
AU2001261832A1 (en) 2001-11-20
NO20025343D0 (no) 2002-11-07
BR0110473A (pt) 2003-04-01
KR20030019372A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
Tarhini et al. Management of brain metastases in patients with melanoma
MY121548A (en) Compounds and methods for the treatment of cancer
MY119403A (en) Novel compounds with analgesic effect.
IL130823A0 (en) Peptide-lipid conjugates liposomes and liposomal drug delivery
EP0719147A4 (en) GENE THERAPY FOR SOLID TUMORS, PAPILLOMAS AND WARTS
CA2361617A1 (en) Uses of thank, a tnf homologue that activates apoptosis
AU5924199A (en) Methods and apparatus for improved administration of fentanyl and sufentanil
AU3091597A (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
PL343462A1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP2020237A3 (en) Ceramide and chemotherapeutic agents for inducing cell death
AU2003273176A8 (en) Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
MXPA02010974A (es) Metodos para inhibir la proliferacion e inducir apoptosis en celulas carcerosas.
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
DE69926251D1 (de) Verfahren zum vernichten von tumoren und tumor-assoziierten endothelialzellen mit adenoviralen mutanten
BG105572A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2002022145A3 (en) Components of canola for the treatment of cancer
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
WO2000020026A3 (en) Compositions and methods for inhibiting angiogenesis
MY133682A (en) Substituted pyrroles
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
MY155221A (en) Renal cell carcinoma treatment
YU43302A (sh) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
Wang et al. EP02. 01-07 DEPDC1 Expression and Mechanisms in Lung Adenocarcinoma: Insights into Proliferation and KIF2C Regulation